MACHOVÁ POLÁKOVÁ, Kateřina, Václava POLÍVKOVÁ, Jana RULCOVÁ, Hana KLAMOVÁ, Tomáš JURČEK, Dana DVOŘÁKOVÁ, Daniela ŽÁČKOVÁ, Zdeněk POSPÍŠIL, Jiří MAYER a Jana MORAVCOVÁ. Constant BCR-ABL transcript level >or=0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis. Experimental hematology. Netherlands: Elsevier Science Inc, 2010, roč. 38, č. 1, s. 20-26. ISSN 0301-472X. |
Další formáty:
BibTeX
LaTeX
RIS
@article{869378, author = {Machová Poláková, Kateřina and Polívková, Václava and Rulcová, Jana and Klamová, Hana and Jurček, Tomáš and Dvořáková, Dana and Žáčková, Daniela and Pospíšil, Zdeněk and Mayer, Jiří and Moravcová, Jana}, article_location = {Netherlands}, article_number = {1}, keywords = {BCR-ABL; CML; imatinib}, language = {eng}, issn = {0301-472X}, journal = {Experimental hematology}, title = {Constant BCR-ABL transcript level >or=0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis.}, volume = {38}, year = {2010} }
TY - JOUR ID - 869378 AU - Machová Poláková, Kateřina - Polívková, Václava - Rulcová, Jana - Klamová, Hana - Jurček, Tomáš - Dvořáková, Dana - Žáčková, Daniela - Pospíšil, Zdeněk - Mayer, Jiří - Moravcová, Jana PY - 2010 TI - Constant BCR-ABL transcript level >or=0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis. JF - Experimental hematology VL - 38 IS - 1 SP - 20-26 EP - 20-26 PB - Elsevier Science Inc SN - 0301472X KW - BCR-ABL KW - CML KW - imatinib N2 - OBJECTIVE: Of 140 chronic myeloid leukemia patients responding to imatinib with complete cytogenetic remission, 32 exhibited a plateau of BCR-ABL values at >or=0.1% level in a minimum of three subsequent samples (minimal duration, 6 - 9 months). Median follow-up of unchanged BCR-ABL transcript level was 12 months (range, 6 - 64). We tested this group of patient for BCR-ABL mutations to reveal resistance development and to evaluate the risk of disease progression. RESULTS: Mutation was detected by direct sequencing in 9 of 32 patients (28%). Loss of complete cytogenetic remission or 1 log rise of BCR-ABL was observed in five of nine patients at a median of 5 months (range, 4-17) since first detection of mutation. One patient with no mutation relapsed 12 months after the start of the BCR-ABL plateau. In 5 of 32 patients without mutation (16%), BCR-ABL level significantly decreased after the first plateau to levels that stayed unchanged for a median of 11 months (range, 7-28). ER -
MACHOVÁ POLÁKOVÁ, Kateřina, Václava POLÍVKOVÁ, Jana RULCOVÁ, Hana KLAMOVÁ, Tomáš JURČEK, Dana DVOŘÁKOVÁ, Daniela ŽÁČKOVÁ, Zdeněk POSPÍŠIL, Jiří MAYER a Jana MORAVCOVÁ. Constant BCR-ABL transcript level \&{}gt;or=0.1\%{} (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis. \textit{Experimental hematology}. Netherlands: Elsevier Science Inc, 2010, roč.~38, č.~1, s.~20-26. ISSN~0301-472X.
|